Description:

https://clinicaltrials.gov/show/NCT00989664 Central Pathology Assessment Study ID: 104504 Clinical Study ID: BEX104504 Study Title: Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas that have Transformed to Higher Grade Histologies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00989664 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Link:

https://clinicaltrials.gov/show/NCT00989664

Keywords:
Versions (2) ▾
  1. 5/25/18
  2. 9/20/21
Copyright Holder:
GlaxoSmithKline (GSK)
Uploaded on:

September 20, 2021

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy NCT00989664

Central Pathology Assessment

Central Pathology Assessment
Biopsy Number
Working Formulation Classification: Histology
Histology - Cell types
Central Pathologist Assessment
Transformed Low-Grade NHL
Basis of Assessment
Pathology Assessment Description
Concordance with Original Pathology Report:
Concordance with Study Site Pathology Report:
Administration

Similar models